Breast cancer treatment and ovarian failure: Risk factors and emerging genetic determinants

Vered Stearns, Bryan Schneider, N. Lynn Henry, Daniel F. Hayes, David A. Flockhart

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Most premenopausal women diagnosed with primary breast cancer receive adjuvant chemotherapy, and many experience chemotherapy-induced ovarian failure (CIOF). CIOF is associated with menopausal symptoms, fertility concerns and long-term implications including bone loss. Ironically, CIOF might confer a disease-specific benefit to women whose breast cancers express hormone receptors. Risk factors of CIOF include the woman's age at the time of therapy, and the type, dose and schedule of chemotherapy. Because inherited genetic factors have an important role in determining who will experience CIOF, genetic testing has the potential to provide optimal counselling about risks and possible interventions.

Original languageEnglish
Pages (from-to)886-893
Number of pages8
JournalNature Reviews Cancer
Volume6
Issue number11
DOIs
StatePublished - Nov 12 2006

Fingerprint

Treatment Failure
Breast Neoplasms
Drug Therapy
Genetic Testing
Adjuvant Chemotherapy
Fertility
Counseling
Appointments and Schedules
Hormones
Bone and Bones

ASJC Scopus subject areas

  • Cancer Research

Cite this

Breast cancer treatment and ovarian failure : Risk factors and emerging genetic determinants. / Stearns, Vered; Schneider, Bryan; Henry, N. Lynn; Hayes, Daniel F.; Flockhart, David A.

In: Nature Reviews Cancer, Vol. 6, No. 11, 12.11.2006, p. 886-893.

Research output: Contribution to journalArticle

Stearns, Vered ; Schneider, Bryan ; Henry, N. Lynn ; Hayes, Daniel F. ; Flockhart, David A. / Breast cancer treatment and ovarian failure : Risk factors and emerging genetic determinants. In: Nature Reviews Cancer. 2006 ; Vol. 6, No. 11. pp. 886-893.
@article{f18b672aa63647dc88f541fc58cee554,
title = "Breast cancer treatment and ovarian failure: Risk factors and emerging genetic determinants",
abstract = "Most premenopausal women diagnosed with primary breast cancer receive adjuvant chemotherapy, and many experience chemotherapy-induced ovarian failure (CIOF). CIOF is associated with menopausal symptoms, fertility concerns and long-term implications including bone loss. Ironically, CIOF might confer a disease-specific benefit to women whose breast cancers express hormone receptors. Risk factors of CIOF include the woman's age at the time of therapy, and the type, dose and schedule of chemotherapy. Because inherited genetic factors have an important role in determining who will experience CIOF, genetic testing has the potential to provide optimal counselling about risks and possible interventions.",
author = "Vered Stearns and Bryan Schneider and Henry, {N. Lynn} and Hayes, {Daniel F.} and Flockhart, {David A.}",
year = "2006",
month = "11",
day = "12",
doi = "10.1038/nrc1992",
language = "English",
volume = "6",
pages = "886--893",
journal = "Nature Reviews Cancer",
issn = "1474-175X",
publisher = "Nature Publishing Group",
number = "11",

}

TY - JOUR

T1 - Breast cancer treatment and ovarian failure

T2 - Risk factors and emerging genetic determinants

AU - Stearns, Vered

AU - Schneider, Bryan

AU - Henry, N. Lynn

AU - Hayes, Daniel F.

AU - Flockhart, David A.

PY - 2006/11/12

Y1 - 2006/11/12

N2 - Most premenopausal women diagnosed with primary breast cancer receive adjuvant chemotherapy, and many experience chemotherapy-induced ovarian failure (CIOF). CIOF is associated with menopausal symptoms, fertility concerns and long-term implications including bone loss. Ironically, CIOF might confer a disease-specific benefit to women whose breast cancers express hormone receptors. Risk factors of CIOF include the woman's age at the time of therapy, and the type, dose and schedule of chemotherapy. Because inherited genetic factors have an important role in determining who will experience CIOF, genetic testing has the potential to provide optimal counselling about risks and possible interventions.

AB - Most premenopausal women diagnosed with primary breast cancer receive adjuvant chemotherapy, and many experience chemotherapy-induced ovarian failure (CIOF). CIOF is associated with menopausal symptoms, fertility concerns and long-term implications including bone loss. Ironically, CIOF might confer a disease-specific benefit to women whose breast cancers express hormone receptors. Risk factors of CIOF include the woman's age at the time of therapy, and the type, dose and schedule of chemotherapy. Because inherited genetic factors have an important role in determining who will experience CIOF, genetic testing has the potential to provide optimal counselling about risks and possible interventions.

UR - http://www.scopus.com/inward/record.url?scp=33750287996&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750287996&partnerID=8YFLogxK

U2 - 10.1038/nrc1992

DO - 10.1038/nrc1992

M3 - Article

C2 - 17036039

AN - SCOPUS:33750287996

VL - 6

SP - 886

EP - 893

JO - Nature Reviews Cancer

JF - Nature Reviews Cancer

SN - 1474-175X

IS - 11

ER -